Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144754 · ClinicalTrials.gov registry record
Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT
A clinical trial, sponsored by Stanford University.
- Terminated
- Registry status
- 1
- Enrollment target
NCT01144754: Clinical Trial study, sponsored by Stanford University.
NCT01144754 is a clinical trial that was terminated before completion, run by Stanford University. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01144754 was terminated before completion, sponsored by Stanford University.
- TERMINATED
- Registry status
- 1 participants
- Enrollment target
Study Summary
This is a multi-center observational study to assess addition of Rituximab in the treatment of previously untreated patients with Diffuse Large B-Cell Lymphomas(DLBCL) over an enrollment period of 60 months. Patients in this study are enrolling for the collection of their data on observations made during normal clinical practice.
Interventions
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2009-02 |
| Est. Completion | 2012-04 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01144754
The ClinicalTrials.gov registry entry for NCT01144754 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rituximab is the first listed.
NCT01144754 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01144754 about?
NCT01144754 is a clinical study titled "Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT". This is a multi-center observational study to assess addition of Rituximab in the treatment of previously untreated patients with Diffuse Large B-Cell Lymphomas(DLBCL) over an enrollment period of 60 months. Patients in this study are enrolling for the collection of their data on observations made d...
What is the current status of trial NCT01144754?
This trial is currently terminated. The enrollment target is 1 participants. The study started on 2009-02. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01144754?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT01144754?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.